5 news items
Cassava Sciences Reports Clinical Updates On Phase 3 Trials Of Simufilam
SAVA
10 May 24
risk/benefit for simufilam 100 mg twice-daily versus placebo in a large population of people with Alzheimer's disease over 12 and 18 months
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
SAVA
10 May 24
with mild-to-moderate Alzheimer's disease dementia. The goal is to evaluate overall risk/benefit for simufilam 100 mg twice-daily versus placebo
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
SAVA
1 May 24
was a taxable event; comments made by our employees regarding the warrant distribution, simufilam, and potential benefits, if any, of our product
Redemption Date Announced for Warrants
SAVA
15 Apr 24
of a warrant was a taxable event; comments made by our employees regarding the warrant distribution, simufilam, and potential benefits, if any, of our product
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
SAVA
25 Mar 24
to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates in people with Alzheimer's disease
- Prev
- 1
- Next